parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in tuft cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	16 Parkinson's papers of 333	0.63
pathways Reactome	2 pathways; mostly lysosome and autophagy	1.00

No case: the score is under the bar. Receipt 7467

receipt 7474: ATG9A in dopamine neurons, braak

power: full sample -0.22 (p 0.379, n 18), 95% CI -0.62 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.22 (p 0.379, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.173, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.13, sign flips 0; without severely affected donors -0.22 (p 0.379, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATG9A in dopamine neurons.

case closed: nothing better to follow up.

receipt 7473: ATG9A in oligodendrocytes, braak

power: full sample -0.47 (p 0.050, n 18), 95% CI -0.77 to -0.00. the interval excludes zero: something may be there, smaller than a half can see.
confounder: adjusted for sex: -0.53 (p 0.025, n 18). holds up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.53 (p 0.025, n 18). not the mix.
skeptic: leave-one-out range -0.58 to -0.40, sign flips 0; without severely affected donors -0.47 (p 0.050, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ATG9A in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts